An additional trial on the optimal treatment of patients with oligometastatic PCa (the LUNAR study (NCT05496959, ClinicalTrials.gov) is exploring the use of 177Lutetium PSMA radioligand before SRT targeting the positive sites on PSMA PET/CT. This evidence concerns the gene FOLH1 and posterior cortical atrophy.